Mater Researcher and clinician-scientist, Dr Joshua Tobin has been selected by the American Society of Hematology (ASH) to receive the 2021 ASH Global Research Award.

Since 2006, Smiling for Smiddy has raised over $10 million for world-class research projects at Mater Research in areas of melanoma, prostate, breast and ovarian cancers. 

Launched in early September, the taskforce has begun to help raise awareness for Australian living with blood cancers to get the help they need.

The Blood Cancer Taskforce, a collaboration of some of the country’s top blood cancer experts and leaders launched today.

Mater researchers, in partnership with The University of Queensland, have achieved publication in the highly-ranked journal ‘Clinical and Translational Immunology’.

Grant success allows research to progress to clinical trails for post chemotherapy gynaecological cancer patients.

Mater Researcher A/Prof Kristen Radford has been awarded a 2020 Fulbright Future Scholarship allowing her to progress her cancer research with a four month sabbatical at the Tisch Cancer Institute.

Mater Research CEO Professor Maher Gandhi has been appointed to a new National Blood Cancer Taskforce to deliver Australia’s first National Strategic Action Plan for Blood Cancer.

Mater Research CEO and MRI-UQ Director Professor Maher Gandhi and his team report that immune-infiltration is a promising tool to improve outcomes for patients with follicular lymphoma.

More Australians living with follicular lymphoma could benefit from tailored treatment through development of a new clinical scoring model thanks to Mater Research.

A Mater researcher has developed a method to predict breast cancer patient responses to a commonly prescribed breast cancer drug.

Prof John Hooper & his team are working towards improving the diagnosis & treatment of ovarian cancer by developing a unique PET imaging agent that shows the exact location and extent of the tumour.